Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206973 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2SLC22A6KMT2AMAPTGABRR1 | |
| SCHEMBL9040323 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2SLC22A6KMT2AMAPTGABRR1 | |
| Ammonia Solution, Strong SCHEMBL21219123 | 0.98 | SMN1; SMN2 (0.50) | SMN1; SMN2SLC22A6KMT2AMAPTGABRR1 | |
| SCHEMBL10933476 | 0.98 | SMN1; SMN2 (0.50) | SMN1; SMN2SLC22A6KMT2AMAPTGABRR1 | |
| Ethylene SCHEMBL5860683 | 0.95 | SMN1; SMN2 (0.48) | SMN1; SMN2SLC22A6KMT2AMAPTGABRR1 | |
| Acrylamide SCHEMBL28172860 | 0.84 | TSHR (0.39) | SMN1; SMN2SLC22A6KMT2AGABRR1LMNA | |
| SCHEMBL8627026 | 0.84 | SMN1; SMN2 (0.36) | SMN1; SMN2SLC22A6KMT2AMAPTTSHR | |
| SCHEMBL1691025 | 0.80 | TSHR (0.43) | SMN1; SMN2KMT2AMAPTTSHRCA1 | |
| SCHEMBL8060426 | 0.80 | ALDH1A1 (0.42) | SMN1; SMN2KMT2ALMNATDP1TSHR | |
| SCHEMBL1823637 | 0.80 | TSHR (0.43) | SMN1; SMN2KMT2AMAPTTSHRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590117-B2 | Hexose derivatives, preparation and uses thereof | FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA (PT) | 2026-03-31 | — | — | US | disclosed |
| US-20230357301-A1 | HEXOSE DERIVATIVES, PREPARATION AND USES THEREOF | FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA (PT) | 2023-11-09 | — | — | US | disclosed |
| US-11708387-B2 | Hexose derivatives, preparation and uses thereof | FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA (PT) | 2023-07-25 | — | — | US | disclosed |
| CN-115448964-A | Hexose derivatives and their formulations and use | 里斯本大学科学与技术学院 | 2022-12-09 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11439993-B2 | Chiral binuclear metal complexes for stereoselective hydrolysis of saccharides and glycosides | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2022-09-13 | — | — | US | disclosed |
| CN-107949562-B | Positive allosteric modulators of muscarinic M2 receptors | 拜耳制药股份公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210101138-A1 | CHIRAL BINUCLEAR METAL COMPLEXES FOR STEREOSELECTIVE HYDROLYSIS OF SACCHARIDES AND GLYCOSIDES | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2021-04-08 | — | — | US | disclosed |
| US-10870103-B2 | Chiral binuclear metal complexes for stereoselective hydrolysis of saccharides and glycosides | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2020-12-22 | — | — | US | disclosed |
| EP-3307741-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARIC M2 RECEPTOR | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-20120058107-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-03-08 | — | — | US | disclosed |
| US-20110301353-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2011-12-08 | — | — | US | disclosed |
| US-8012966-B2 | Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2011-09-06 | — | — | US | disclosed |
| WO-2011026781-A1 | NOVEL MULTIFUNCTIONAL PEPTIDASE INHIBITORS, ESPECIALLY FOR MEDICAL USE | IMTM GMBH (DE) | 2011-03-10 | — | — | WO | disclosed |
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD (CN) | 2010-03-25 | — | — | US | disclosed |
| US-20100004239-A1 | Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2010-01-07 | — | — | US | disclosed |
| EP-1001951-B1 | THIAZOLE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND USE | SCHERING AG (DE) | 2002-09-25 | — | — | EP | disclosed |
| US-6384230-B1 | 2,6-DIMETHYL-5-((4-ETHOXYPHENYL)-METHOXY)-7-(2-METHYLTHIAZOL-4-YL)HEPTA -2,6-DIENOIC ACID ETHYL ESTER FROM MALIC ACID, WITTIG REACTION WITH 2-METHYL-4-THIAZOLYLMETHYL TRIPHENYL PHOSPHONIUM BROMIDE; INTERMEDIATES FOR EPOTHILONE A OR B | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-05-07 | — | — | US | disclosed |
| EP-1001951-A1 | THIAZOLE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999003848-A1 | THIAZOLE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND USE | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058107-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | DMPK, PDPK1, PRKAR2A | SMN1; SMN2 4128/4885SLC22A6 4348/4885KMT2A 2095/4885 |
| US-20110301353-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | DMPK, PDPK1, PRKAR2A | SMN1; SMN2 4128/4885SLC22A6 4348/4885KMT2A 2095/4885 |
| US-20230357301-A1 | HEXOSE DERIVATIVES, PREPARATION AND USES THEREOF | HK1, SLC5A1, HK2 | SMN1; SMN2 2954/4885SLC22A6 160/4885KMT2A 3060/4885 |
| US-10870103-B2 | Chiral binuclear metal complexes for stereoselective hydrolysis of saccharides and glycosides | MANBA, HEXB, GALE | SMN1; SMN2 4015/4885SLC22A6 1335/4885KMT2A 2635/4885 |
| US-20100075952-A1 | PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF | MTOR, PKN2, MAP3K15 | SMN1; SMN2 4172/4885SLC22A6 3991/4885KMT2A 2878/4885 |
| US-20210101138-A1 | CHIRAL BINUCLEAR METAL COMPLEXES FOR STEREOSELECTIVE HYDROLYSIS OF SACCHARIDES AND GLYCOSIDES | MANBA, HEXB, GALE | SMN1; SMN2 4015/4885SLC22A6 1335/4885KMT2A 2635/4885 |
| US-11439993-B2 | Chiral binuclear metal complexes for stereoselective hydrolysis of saccharides and glycosides | MANBA, HEXB, GALE | SMN1; SMN2 4015/4885SLC22A6 1335/4885KMT2A 2635/4885 |
| US-20100004239-A1 | Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors | DMPK, CDK2, PRKAR2A | SMN1; SMN2 4148/4885SLC22A6 4374/4885KMT2A 1915/4885 |
| US-12590117-B2 | Hexose derivatives, preparation and uses thereof | SLC5A1, HK1, SLC5A2 | SMN1; SMN2 2000/4885SLC22A6 281/4885KMT2A 3854/4885 |
| US-11708387-B2 | Hexose derivatives, preparation and uses thereof | HK1, SLC5A1, HK2 | SMN1; SMN2 2954/4885SLC22A6 160/4885KMT2A 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.